SPARC — Sun Pharma Advanced Research Co Income Statement
0.000.00%
Last trade - 00:00
- IN₹83.52bn
- IN₹79.87bn
- IN₹2.39bn
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,829 | 768 | 2,530 | 1,372 | 2,388 |
Cost of Revenue | |||||
Gross Profit | 1,612 | 198 | 2,163 | 1,065 | 2,045 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,350 | 3,918 | 3,987 | 3,333 | 4,624 |
Operating Profit | -1,521 | -3,150 | -1,457 | -1,961 | -2,236 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1,454 | -3,124 | -1,511 | -2,034 | -2,226 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1,454 | -3,124 | -1,511 | -2,034 | -2,226 |
Net Income Before Extraordinary Items | |||||
Net Income | -1,454 | -3,124 | -1,511 | -2,034 | -2,226 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1,454 | -3,124 | -1,511 | -2,034 | -2,226 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -5.61 | -11.9 | -5.78 | -7.92 | -7.81 |